Notably, the FLOW trial confirmed that semaglutide, a GLP-1 receptor agonist, significantly reduced the incidence of composite kidney outcomes and cardiovascular mortality in patients with type 2 diabetes and CKD, thus reinforcing the value of early detection and intervention (12). Here, GLP1R is linked to type 2 diabetes mellitus.